Inicio > Bioquímica. Química orgánica > Mecanismos moleculares involucrados en la fisiopatología del estrés nitrooxidativo > Página 4

Mecanismos moleculares involucrados en la fisiopatología del estrés nitrooxidativo

  1. inducible nitric oxide synthase. Crit Care Med 2005; 33 (4).
  2. Tessari P. Acute effect of insulin on nitric oxide synthesis in humans: a precursor – product isotopic study. Am J Physiol Endocrinol Metab 2007; 293: 776 – 82.
  3. Bolander F. Prolactin activation of mammary nitric oxide synthase: molecular mechanisms. Journal of Molecular Endocrinology 2002; 48: 25 – 51.
  4. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard KA, Sessa WC. Phosphorilation of threonine 497 in endothelial nitric oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. Journal of Biological Chemistry 2003; 278(45): 44719 – 26.
  5. Russwurm M, Koesling D. Guanylyl cyclase: NO hits its target. Biochemical Society Symposia 2004; 71: 51 – 63.
  6. Garthwaite J. Dynamics of cellular NO-cGMP signaling. Frontiers in Bioscience 2005; 10: 1868 – 80.
  7. López – Jaramillo P, Zarruki JG, García RG, Tomas C. Oxido nítrico, función endotelial y trastorno depresivo mayor. Rev Med 2006; 14 (1): 19 – 29.
  8. Bamidón L, Martínez J. Disfunción endotelial. Rev Esp Cardiol 2006; 6: 21 – 30.
  9. Davis N, Katz S, Wylie – Rosett J. The effect of diet on endothelial function. Cardiology in Review 2007; 15: 62 – 6.
  10. Vela R, García JV, Cabrera J, González C, Pérez SC, Farre J. impotencia y enfermedad cardiovascular: una nueva perspectiva en el compromiso asistencial del urólogo. Arch Esp Urol 2005; 58 (1).
  11. Duarte J, Espinosa R, Díaz S, Sánchez G, Lee EV, Mijangos J, Barragán JA. Oxido nítrico: metabolismo e implicaciones clínicas. Med Int Mex 2008; 24 (6): 397 – 406.
  12. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase in atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology 2004; 24: 998-1005.
  13. Pantelis A. Insulin and endothelin: an interplay contributing to hypertension development. J Clin Endocrinol Metab 2007; 92 (2): 379 – 85.
  14. Cifuentes, ME, Pagano P. Targeting reactive oxygen species in hypertension. Current opinion in Nephrology and Hypertension 2006; 15: 179 – 86.
  15. Benítez, D. Vitaminas y oxidorreductasas antioxidantes: defensa ante el estrés oxidativo. Rev Cubana Invest Bioméd 2006; 25 (2).
  16. Muravchick S, Levy R. Clinical implication of mitochondrial dysfunction. Anesthesiology 2006; 105: 819 – 37.
  17. Nageswara R, Runge M. Mitochondrial dysfunction in Atherosclerosis. Circ Res 2007; 100: 460 – 73.
  18. Norata GD, Catapanp AL. Molecular mechanisms responsible for the anti – inflammatory and protective effect of high density lipoprotein on the endothelium. High Bloo Press Cardiovasc Prev 2007; 14 (2): 69 – 73.
  19. Toda N, Toda H, Hatano Y. Nitric oxide. Involment in the effect of anesthetic agents. Anaesthesiology 2007; 107: 822 – 42.
  20. Avette CL. Exogenous arginine in sepsis. Crit Care Med 2007; (35): 557 – 63.
  21. Sigfrid L. Cytokines and nitric oxide inhibit the enzyme activity of catalase but not its protein or mRNA expression in insulin – producing cells. Journal of Molecular Endocrinology 2003; 31: 509 – 18.
  22. Benavides MC, Pinzón A. Oxido nítrico: implicaciones fisiopatológicas. Rev Col Anest, 2008; 36: 45 – 52.
  23. Ferdinandy P, Schulz P. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia – reperfusion injury and preconditioning. British Journal of Pharmacology 2003, 138: 532 – 43.
  24. Tenorio F, Torres N, Zarco G, Díaz J, Pastelín G, del Valle L. El óxido nítrico y las enfermedades cardiovasculares: cardioprotección versus cardiotoxicidad. Rev Mex Ciencias Farmacéuticas 2008; 39 (3): 39 – 48.